AstraZeneca’s Farxiga Gets Fast Track Designation for Heart Failure

The FDA has granted a Fast Track designation to AstraZeneca’s Farxiga (dapagliflozin) for reducing the risk of hospitalization for heart failure or cardiovascular death in adults following a heart attack.

AstraZeneca plans to conduct a phase 3 trial to study the drug’s safety and efficacy in that patient population.

Farxiga was approved by the agency in May for reducing the risk of hospitalization and cardiovascular death in adults with heart failure when their left ventricle is not pumping normally.